hGH fragment is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-12-27. Numbers and descriptions here follow the published literature rather than marketing material.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
=== Cell integrity loss === Cell integrity loss is caused by bacteria releasing dissolved algicidal compounds, which are toxic to algae, into the surrounding water, causing rapid cell lysis of algae cells. Cell lysis occurs when algicidal enzymes or small molecules degrade cell walls and membranes, causing structural collapse. While most compounds released by algicidal bacteria cause cell lysis by damaging the algae cells walls, other lysis inducing mechanisms can include ion permeability disruption, and acidification of the cytoplasm by small molecules passing through the cell wall. An example of a bacterium which causes cell integrity loss is a strain of Alteromonas abrolhosensis, named JY‑JZ1, which when cultured, showed strong algicidal activity. Through microscopy, researchers found that algal cells exposed to this bacterium had damaged cell membranes and leaked intracellular contents which indicates cell death by lysis.
In Korean cuisine, glass noodles are usually made from sweet potato starch and are called dangmyeon (Korean: 당면; Hanja: 唐麵; literally "Tang noodles"; also spelled dang myun, dangmyun, tang myun, or tangmyun). They are commonly stir-fried in sesame oil with beef and vegetables, and flavoured with soy and sugar, in a popular dish called japchae (잡채). They are usually thick, and are a brownish-gray color when in their uncooked form.
== Epidemiology == Kwashiorkor is rare in high-income countries. It is mostly observed in low-income and middle-income nations and regions such as Southeast Asia, Central America, Congo, Ethiopia, Puerto Rico, Jamaica, South Africa, and Uganda, where poverty is prominent. Occurrences of severe malnutrition also tend to trend higher under conditions of food insecurity, higher prevalence of infectious diseases, lack of access to appropriate care, and poor living situations with inadequate sanitation. Communities experiencing famine are affected the most, especially during the rainy season. Prevalence varies, but it affects children of either sex commonly under five years old. "Globally, kwashiorkor indirected accounted for 53% of deaths among children under five between 2000 and 2003 when associated with other common childhood diseases like acute respiratory infections, malaria, measles, HIV/AIDS and other causes of perinatal deaths." When compared to marasmus in developing countries, kwashiorkor typically has a lower prevalence, "0.2%-1.6% for kwashiorkor and 1.2%-6.8% for marasmus." Factors such as "diet, geographical locations, climate, and aflatoxin exposure" have been invoked as potential causes for observed differences in the prevalence of kwashiorkor and marasmus. In general, in areas where Severe Acute Malnutrition (SAM) is prevalent, marasmus is more often the dominant SAM condition. However, in certain areas, kwashiorkor may be more common than marasmus.
Drug discovery is the initial phase of research focused on identifying and validating new chemical compounds (lead compounds) that are intended to treat a disease. Drug design is an inventive method used within the discovery phase and encompasses the designing of molecules that are complementary in polarity (charge) and shape (stereochemistry) to a given biomolecular target. After a lead compound has been identified through drug discovery, drug development involves bringing the drug to the market. Drug discovery is related to pharmacoeconomics, which is the sub-discipline of health economics that considers the value of drugs. Pharmacoeconomics evaluates the cost and benefits of drugs in order to guide optimal healthcare resource allocation. The techniques used for the formulation and manufacturing of drugs are studied by pharmaceutical engineering, a branch of engineering. Safety pharmacology specializes in detecting and investigating potential undesirable and adverse effects of drugs.
== History == Teicoplanin was first isolated in 1978 from Actinoplanes teichomyceticus (ATCC 31121), a rare species of actinobacteria in the family Micromonosporaceae. The bacteria were obtained from a soil sample collected in Nimodi Village, Indore, India. The chemical structure of teicoplanin was determined and published in 1984. Teicoplanin was first introduced into clinical use in 1984. Following the publication of studies demonstrating its efficacy against infections such as bone and soft tissue infections, endocarditis, pneumonia, and sepsis in 1986, it received regulatory approval in Europe in 1988. The biosynthetic pathway leading to teicoplanin, as well as the regulatory circuit governing the biosynthesis, were studied intensively in recent years, allowing for the creation of an integrated model of its biosynthesis.
Sources: en.wikipedia.org
=== Pharmacology === Doxycycline, at subantimicrobial doses, inhibits MMP activity, and has been used in various experimental systems for this purpose, such as for recalcitrant recurrent corneal erosions. It is used clinically for the treatment of periodontal disease and is the only MMP inhibitor that is widely available clinically. It is sold under the trade name Periostat by the company CollaGenex. Minocycline, another tetracycline antibiotic, has also been shown to inhibit MMP activity. A number of rationally designed MMP inhibitors have shown some promise in the treatment of pathologies that MMPs are suspected to be involved in (see above). However, most of these, such as marimastat (BB-2516), a broad-spectrum MMP inhibitor, and cipemastat (Ro 32-3555), an MMP-1 selective inhibitor, have performed poorly in clinical trials. The failure of Marimastat was partially responsible for the folding of British Biotech, which developed it. The failure of these drugs has been due largely to toxicity (in particular, musculo-skeletal toxicity in the case of broad spectrum inhibitors) and failure to show expected results (in the case of trocade, promising results in rabbit arthritis models were not replicated in human trials). The reasons behind the largely disappointing clinical results of MMP inhibitors is unclear, especially in light of their activity in animal models.
=== Channel 5 === In 2010, Willis replaced Melinda Messenger on the Channel 5 series Live from Studio Five, but she left after only two months to co-present Big Brother's Little Brother and was replaced by Jayne Middlemiss. In August 2011, she returned to the revived series, presenting the spin-off show Big Brother's Bit on the Side. On 13 March 2013, it was reported that Brian Dowling would be axed from Big Brother and be replaced by Willis with a source saying, 'Brian has been a great host but Emma is seen by channel chiefs as a true successor to Davina. They're talking to her now about taking over the role from the summer.' Her appointment as host was confirmed on 2 April 2013. On 13 June 2013, she began presenting the fourteenth series of Big Brother. As well as presenting the main Big Brother and celebrity series, she continued to host the spin-off show Bit on the Side, sharing the presenting duties with Rylan Clark. On 2 February 2015, it was announced that Willis was to present her final edition of Bit on the Side that night, and Clark would take over as the main presenter of the spin off show. Willis interrogated Winston McKenzie during his exit interview on Celebrity Big Brother over his controversial opinions. Willis has expressed personal pride on this moment in her career. On 30 March 2014, Willis presented the Mum of the Year Awards, with the highlights being shown on Channel 5 that same evening.
She played the role of Amelia Slater in the Fox series Pitch, about Ginny Baker (Kylie Bunbury), a young black woman who makes history by becoming the first woman to play for a Major League Baseball team. The series ran for a season, which was released in 2016. From 2019 to 2020, Larter acted in the recurring role of Grace Sawyer in the police procedural series The Rookie on ABC In 2021, she played the lead role in the neo-western film The Last Victim. She starred in the thriller The Man in the White Van, which premiered at the 2023 Newport Beach Film Festival and was released in December 2024 to mixed reviews. In 2024, Larter co-starred in Taylor Sheridan’s show Landman, starring Billy Bob Thornton. Larter plays Angela Norris, a “cartoonish” funny caricature of a gold-digging ex-wife.
=== Psoriasis and psoriatic arthritis === Psoriasis is a skin condition characterized by the rapid buildup of skin cells, leading to scaling on the skin's surface. Inflammation and redness around the scales is common. Some individuals with psoriasis also develop psoriatic arthritis, which causes joint pain, stiffness, and swelling.
The Ancient Greek word for bone is ὀστέον ("osteon"). In anatomical terminology, including in the Terminologia Anatomica, the word for a bone is os (for example, os breve, os longum, os sesamoideum). (This is not to be confused with the alternative medical use of os to mean orifice, from the Latin ōs, mouth.)
Sources: en.wikipedia.org
=== Goodpasture syndrome === The alpha-3 subunit (COL4A3) of collagen IV is thought to be the antigen implicated in Goodpasture syndrome, wherein the immune system attacks the basement membranes of the glomeruli and the alveoli upon the antigenic site on the alpha-3 subunit becoming unsequestered due to environmental exposures. Goodpasture syndrome presents with nephritic syndrome and hemoptysis. Microscopic evaluation of biopsied renal tissue will reveal linear deposits of Immunoglobulin G by immunofluorescence. This is classically in young adult males.
Compounds with krypton bonded to atoms other than fluorine have also been discovered. There are also unverified reports of a barium salt of a krypton oxoacid. ArKr+ and KrH+ polyatomic ions have been investigated and there is evidence for KrXe or KrXe+. The reaction of KrF2 with B(OTeF5)3 produces an unstable compound, Kr(OTeF5)2, that contains a krypton-oxygen bond. A krypton-nitrogen bond is found in the cation [HC≡N−Kr−F]+, produced by the reaction of KrF2 with [HC≡NH]+[AsF6]−] below 223 K (−50 °C). HKrCN and HKrC≡CH (krypton hydride-cyanide and hydrokryptoacetylene) were reported to be stable up to 40 K (−233.2 °C). Krypton hydride (Kr(H2)4) crystals can be grown at pressures above 5 GPa. They have a face-centered cubic structure where krypton octahedra are surrounded by randomly oriented hydrogen molecules. The kryptonium ion, KrH+, is an onium ion, consisting of protonated krypton. Kryptonium is known in dilute gas phase. Although salts of the fluorokryptonium ion, KrF+, are known to exist, the existence of the kryptonium salts have not been proven. In 1989, Bergman, Moore, Pimentel and coworkers photolyzed a rhodium(I) complex, Cp*Rh(CO)2 (Cp* = pentamethylcyclopentadienyl), using a pulsed XeCl laser (308 nm) in pressurized liquid Kr as a solvent at a temperature between −80 and −120 °C (193 and 153 K) and observed the formation of Cp*Rh(CO)(Kr), which was identified by infrared spectroscopy by its metal–carbonyl stretch at 1946 cm−1. This species decayed with a rate constant of k = 5 × 103 s−1 at −80 °C (193 K).
=== Avoiding bites === Rattlesnakes tend to avoid wide-open spaces where they cannot hide from predators, and generally avoid humans if they are aware of their approach. Rattlesnakes rarely bite unless they feel threatened or provoked. A majority of victims (about 72%) are males. Around half of bites occur in cases where the victim saw the snake, yet made no effort to move away. Harassing or attacking a rattlesnake, illegal in some jurisdictions, puts one at much higher risk of a bite. Rattlesnakes seek to avoid humans and other predators or large herbivores that themselves pose lethal danger. Dogs, often much more aggressive than humans, are much more likely to experience a snakebite, and are more likely to die of a rattlesnake bite although they can be vaccinated against them. Caution is advised even when snakes are believed to be dead; rattlesnake heads can sense, flick the tongue, and inflict venomous bites reflexively for up to an hour after being severed from the body.
Serotonin itself is too hydrophilic to enter serotonergic neurons without the SERT, whereas serotonergic psychedelics and serotonin's N-methylated metabolites and analogues are lipophilic and readily enter these neurons. These findings may also explain why selective serotonin reuptake inhibitors (SSRIs) and related serotonergic agents do not produce psychedelic effects. The properties of 5-HTP in animal drug discrimination tests have been studied. 5-HTP generalizes with the serotonin releasing agent fenfluramine and its cue is markedly potentiated by the selective serotonin reuptake inhibitor (SSRI) fluoxetine. However, numerous serotonin receptor antagonists, including methysergide, cyproheptadine, metergoline, methiothepin (metitepine), ketanserin, pirenperone, pizotifen, and mianserin, all failed to block the discriminative stimulus properties of 5-HTP. Conflictingly however, in a subsequent study, pizotifen was able to fully block the discriminative stimulus properties of 5-HTP. The inability of serotonin 5-HT2A receptor antagonists to block the discriminative stimulus properties of 5-HTP is in notable contrast to their ability to block the 5-HTP-induced HTR. 5-HTP only partially substitutes for LSD in drug discrimination tests, whereas LSD and quipazine fully substitute for 5-HTP. The full substitution of LSD and quipazine for 5-HTP can be blocked by the serotonin 5-HT2A receptor antagonist ketanserin.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.